Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin

Maturitas ◽  
2006 ◽  
Vol 53 (1) ◽  
pp. 89-96 ◽  
Author(s):  
Inga-Stina Ödmark ◽  
Kjell Carlström ◽  
Björn Jonsson ◽  
Aino Fianu Jonasson
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Carbohydrate Metabolism ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Conjugated Estrogen

Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women

Maturitas ◽  
2002 ◽  
Vol 41 (2) ◽  
pp. 133-141 ◽  
Author(s):  
Inka Wiegratz ◽  
Franz Starflinger ◽  
Wolfgang Tetzloff ◽  
Beate Leifels-Fischer ◽  
Frans A Helmond ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Carbohydrate Metabolism ◽  
Postmenopausal Women ◽  
Hormone Replacement

scholarly journals Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults

2000 ◽  
Vol 143 (6) ◽  
pp. 769-773 ◽  
Author(s):  
M Tschop ◽  
H Lahner ◽  
H Feldmeier ◽  
H Grasberger ◽  
KM Morrison ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Replacement Therapy ◽  
Statistical Significance ◽  
Hormone Replacement ◽  
Human Growth ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Total Serum ◽  
Hormone Binding ◽  
Thyroxine Binding Globulin

OBJECTIVE: To determine if human growth hormone (hGH) replacement therapy alters pharmacokinetics of hydrocortisone (CS) substitution in hypopituitary adults. DESIGN: To this aim, we analysed serum and salivary CS profiles 270 min after oral CS administration at baseline and 6 and 12 months after initiation of hGH replacement therapy. METHODS: Serum IGF-I, cortisol-binding globulin (CBG), thyroxine-binding globulin (TBG) and sex hormone-binding hormone (SHBG) were measured using commercially available radioimmunoassays. In-house immunofluorometric assays were employed for measurements of CS and hGH. RESULTS: hGH replacement did not change total serum CS bioavailability (area under the serum cortisol profile curve). Interference of orally administered CS with salivary measurement of free CS (fCS) caused significant bias. Therefore, fCS levels were calculated from their total CS and cortisol-binding globulin (CBG) levels. CBG decreased by approximately 30% after both 6 and 12 months of hGH replacement therapy (n=20, P<0.01). A significant negative correlation between deltaCBG (CBG6months-CBGbaseline) and deltaIGF-I (IGF-I6months-IGF-Ibaseline) was observed (P=0.04). The calculated values of free CS tended to increase with physiological hGH replacement, but this effect was marginal and did not reach statistical significance. In contrast to the CBG concentrations, plasma levels of sex hormone-binding globulin and thyroxine-binding globulin were essentially stable. CONCLUSION: Given that no clinically relevant alterations in pharmacokinetics of CS were evoked by initiation of hGH replacement in hypopituitary adults, we conclude that CS substitution does not require dose adjustment after initiation of hGH replacement.

Sign in / Sign up

Export Citation Format

Share Document